Summary

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. It is marketed predominantly as the racemate. The free-base molecular formula is C18H19N3O (molecular weight 293.36 g/mol). A commonly used systematic chemical name is (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; commercial products are frequently supplied as ondansetron hydrochloride (often with defined hydration state) to improve handling and aqueous solubility in finished dosage forms.

From a physicochemical standpoint, ondansetron is a weakly basic heteroaromatic ketone (imidazole nitrogen as the principal basic site), typically encountered as an off-white crystalline solid. The free base is sparingly soluble in water with moderate lipophilicity (logP in the low-to-mid single digits), while the hydrochloride salt is substantially more water-soluble and therefore preferred for oral solutions and injectables. Industrial synthesis is generally executed by constructing the carbazol-4-one core (via stepwise ring-forming cyclization on a suitably substituted bicyclic precursor), introducing a 3-(halomethyl) or equivalent electrophilic handle, then performing N-alkylation of 2-methylimidazole to install the imidazolylmethyl side chain; the active base is finally converted to the hydrochloride (and, where applicable, crystallized to a controlled hydrate) under tightly controlled crystallization and polymorph control conditions.

Pharmacologically, ondansetron is a potent and selective antagonist of the 5-HT3 ligand-gated ion channel, blocking serotonin-mediated signaling on peripheral vagal afferents in the gastrointestinal tract and centrally within the chemoreceptor trigger zone and vomiting center, thereby suppressing the emetogenic reflex without relying on dopamine D2 receptor blockade. After oral administration, systemic exposure is limited by first-pass metabolism and shows moderate bioavailability; peak concentrations typically occur within a few hours. Distribution is extensive with moderate plasma protein binding. Clearance is predominantly hepatic oxidative metabolism (CYP3A4 as a major contributor, with CYP2D6 and CYP1A2 also participating), with metabolites eliminated in urine and feces and only a minor fraction recovered unchanged; the terminal half-life in healthy adults is on the order of several hours and is meaningfully prolonged in hepatic impairment, which is the clinically relevant driver for dose limitation in that population.
The global Ondansetron market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Ondansetron is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Ondansetron is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Ondansetron is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Ondansetron include Sun Pharmaceuticals, Sandoz, Qilu Pharmaceutical, Fuan Pharmaceutical, PKU HealthCare, Wockhardt, Aelida Healthcare, Beijing Sciecure Pharmaceutical and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Ondansetron market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ondansetron Market by Company
Sun Pharmaceuticals
Sandoz
Qilu Pharmaceutical
Fuan Pharmaceutical
PKU HealthCare
Wockhardt
Aelida Healthcare
Beijing Sciecure Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Fosun Pharma
Harbin Medisan
CTX Lifesciences
Pfizer
Viatris
Dr. Reddy's Laboratories
Aurobindo Pharma
Zydus Lifesciences
Lupin
Hikma Pharmaceuticals
Fresenius Kabi
Baxter Pharmaceuticals

Ondansetron Segment by Type
Tablets (including ODT)
Injection
ODF/OSF
Other

Ondansetron Segment by Application
Hospital pharmacies
Retail pharmacies
Online pharmacies

Ondansetron Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ondansetron market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ondansetron and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ondansetron.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Ondansetron manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Ondansetron by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Ondansetron in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

ページTOPに戻る

Table of Contents

1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources

2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Ondansetron Market Size (2021-2032)
2.2.2 Global Ondansetron Sales (2021-2032)
2.2.3 Global Ondansetron Market Average Price (2021-2032)
2.3 Ondansetron by Type
2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
2.3.2 Tablets (including ODT)
2.3.3 Injection
2.3.4 ODF/OSF
2.3.5 Other
2.4 Ondansetron by Application
2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.4.2 Hospital pharmacies
2.4.3 Retail pharmacies
2.4.4 Online pharmacies

3 Market Competitive Landscape by Manufacturers
3.1 Global Ondansetron Market Competitive Situation by Manufacturers (2021 Versus 2025)
3.2 Global Ondansetron Sales (kg) of Manufacturers (2021-2026)
3.3 Global Ondansetron Revenue of Manufacturers (2021-2026)
3.4 Global Ondansetron Average Price by Manufacturers (2021-2026)
3.5 Global Ondansetron Industry Ranking, 2024 VS 2025 VS 2026
3.6 Global Manufacturers of Ondansetron, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Ondansetron, Product Type & Application
3.8 Global Manufacturers of Ondansetron, Established Date
3.9 Global Ondansetron Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled
4.1 Sun Pharmaceuticals
4.1.1 Sun Pharmaceuticals Company Information
4.1.2 Sun Pharmaceuticals Business Overview
4.1.3 Sun Pharmaceuticals Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.1.4 Sun Pharmaceuticals Ondansetron Product Portfolio
4.1.5 Sun Pharmaceuticals Recent Developments
4.2 Sandoz
4.2.1 Sandoz Company Information
4.2.2 Sandoz Business Overview
4.2.3 Sandoz Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.2.4 Sandoz Ondansetron Product Portfolio
4.2.5 Sandoz Recent Developments
4.3 Qilu Pharmaceutical
4.3.1 Qilu Pharmaceutical Company Information
4.3.2 Qilu Pharmaceutical Business Overview
4.3.3 Qilu Pharmaceutical Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.3.4 Qilu Pharmaceutical Ondansetron Product Portfolio
4.3.5 Qilu Pharmaceutical Recent Developments
4.4 Fuan Pharmaceutical
4.4.1 Fuan Pharmaceutical Company Information
4.4.2 Fuan Pharmaceutical Business Overview
4.4.3 Fuan Pharmaceutical Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.4.4 Fuan Pharmaceutical Ondansetron Product Portfolio
4.4.5 Fuan Pharmaceutical Recent Developments
4.5 PKU HealthCare
4.5.1 PKU HealthCare Company Information
4.5.2 PKU HealthCare Business Overview
4.5.3 PKU HealthCare Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.5.4 PKU HealthCare Ondansetron Product Portfolio
4.5.5 PKU HealthCare Recent Developments
4.6 Wockhardt
4.6.1 Wockhardt Company Information
4.6.2 Wockhardt Business Overview
4.6.3 Wockhardt Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.6.4 Wockhardt Ondansetron Product Portfolio
4.6.5 Wockhardt Recent Developments
4.7 Aelida Healthcare
4.7.1 Aelida Healthcare Company Information
4.7.2 Aelida Healthcare Business Overview
4.7.3 Aelida Healthcare Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.7.4 Aelida Healthcare Ondansetron Product Portfolio
4.7.5 Aelida Healthcare Recent Developments
4.8 Beijing Sciecure Pharmaceutical
4.8.1 Beijing Sciecure Pharmaceutical Company Information
4.8.2 Beijing Sciecure Pharmaceutical Business Overview
4.8.3 Beijing Sciecure Pharmaceutical Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.8.4 Beijing Sciecure Pharmaceutical Ondansetron Product Portfolio
4.8.5 Beijing Sciecure Pharmaceutical Recent Developments
4.9 Jiangsu Hengrui Pharmaceuticals
4.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
4.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
4.9.3 Jiangsu Hengrui Pharmaceuticals Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.9.4 Jiangsu Hengrui Pharmaceuticals Ondansetron Product Portfolio
4.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
4.10 Fosun Pharma
4.10.1 Fosun Pharma Company Information
4.10.2 Fosun Pharma Business Overview
4.10.3 Fosun Pharma Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.10.4 Fosun Pharma Ondansetron Product Portfolio
4.10.5 Fosun Pharma Recent Developments
4.11 Harbin Medisan
4.11.1 Harbin Medisan Company Information
4.11.2 Harbin Medisan Business Overview
4.11.3 Harbin Medisan Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.11.4 Harbin Medisan Ondansetron Product Portfolio
4.11.5 Harbin Medisan Recent Developments
4.12 CTX Lifesciences
4.12.1 CTX Lifesciences Company Information
4.12.2 CTX Lifesciences Business Overview
4.12.3 CTX Lifesciences Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.12.4 CTX Lifesciences Ondansetron Product Portfolio
4.12.5 CTX Lifesciences Recent Developments
4.13 Pfizer
4.13.1 Pfizer Company Information
4.13.2 Pfizer Business Overview
4.13.3 Pfizer Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.13.4 Pfizer Ondansetron Product Portfolio
4.13.5 Pfizer Recent Developments
4.14 Viatris
4.14.1 Viatris Company Information
4.14.2 Viatris Business Overview
4.14.3 Viatris Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.14.4 Viatris Ondansetron Product Portfolio
4.14.5 Viatris Recent Developments
4.15 Dr. Reddy's Laboratories
4.15.1 Dr. Reddy's Laboratories Company Information
4.15.2 Dr. Reddy's Laboratories Business Overview
4.15.3 Dr. Reddy's Laboratories Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.15.4 Dr. Reddy's Laboratories Ondansetron Product Portfolio
4.15.5 Dr. Reddy's Laboratories Recent Developments
4.16 Aurobindo Pharma
4.16.1 Aurobindo Pharma Company Information
4.16.2 Aurobindo Pharma Business Overview
4.16.3 Aurobindo Pharma Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.16.4 Aurobindo Pharma Ondansetron Product Portfolio
4.16.5 Aurobindo Pharma Recent Developments
4.17 Zydus Lifesciences
4.17.1 Zydus Lifesciences Company Information
4.17.2 Zydus Lifesciences Business Overview
4.17.3 Zydus Lifesciences Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.17.4 Zydus Lifesciences Ondansetron Product Portfolio
4.17.5 Zydus Lifesciences Recent Developments
4.18 Lupin
4.18.1 Lupin Company Information
4.18.2 Lupin Business Overview
4.18.3 Lupin Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.18.4 Lupin Ondansetron Product Portfolio
4.18.5 Lupin Recent Developments
4.19 Hikma Pharmaceuticals
4.19.1 Hikma Pharmaceuticals Company Information
4.19.2 Hikma Pharmaceuticals Business Overview
4.19.3 Hikma Pharmaceuticals Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.19.4 Hikma Pharmaceuticals Ondansetron Product Portfolio
4.19.5 Hikma Pharmaceuticals Recent Developments
4.20 Fresenius Kabi
4.20.1 Fresenius Kabi Company Information
4.20.2 Fresenius Kabi Business Overview
4.20.3 Fresenius Kabi Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.20.4 Fresenius Kabi Ondansetron Product Portfolio
4.20.5 Fresenius Kabi Recent Developments
4.21 Baxter Pharmaceuticals
4.21.1 Baxter Pharmaceuticals Company Information
4.21.2 Baxter Pharmaceuticals Business Overview
4.21.3 Baxter Pharmaceuticals Ondansetron Sales, Revenue and Gross Margin (2021-2026)
4.21.4 Baxter Pharmaceuticals Ondansetron Product Portfolio
4.21.5 Baxter Pharmaceuticals Recent Developments

5 Global Ondansetron Market Scenario by Region
5.1 Global Ondansetron Market Size by Region: 2021 VS 2025 VS 2032
5.2 Global Ondansetron Sales by Region: 2021-2032
5.2.1 Global Ondansetron Sales by Region: 2021-2026
5.2.2 Global Ondansetron Sales by Region: 2027-2032
5.3 Global Ondansetron Revenue by Region: 2021-2032
5.3.1 Global Ondansetron Revenue by Region: 2021-2026
5.3.2 Global Ondansetron Revenue by Region: 2027-2032
5.4 North America Ondansetron Market Facts & Figures by Country
5.4.1 North America Ondansetron Market Size by Country: 2021 VS 2025 VS 2032
5.4.2 North America Ondansetron Sales by Country (2021-2032)
5.4.3 North America Ondansetron Revenue by Country (2021-2032)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Ondansetron Market Facts & Figures by Country
5.5.1 Europe Ondansetron Market Size by Country: 2021 VS 2025 VS 2032
5.5.2 Europe Ondansetron Sales by Country (2021-2032)
5.5.3 Europe Ondansetron Revenue by Country (2021-2032)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Ondansetron Market Facts & Figures by Country
5.6.1 Asia Pacific Ondansetron Market Size by Country: 2021 VS 2025 VS 2032
5.6.2 Asia Pacific Ondansetron Sales by Country (2021-2032)
5.6.3 Asia Pacific Ondansetron Revenue by Country (2021-2032)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Ondansetron Market Facts & Figures by Country
5.7.1 South America Ondansetron Market Size by Country: 2021 VS 2025 VS 2032
5.7.2 South America Ondansetron Sales by Country (2021-2032)
5.7.3 South America Ondansetron Revenue by Country (2021-2032)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.7.7 Colombia
5.8 Middle East and Africa Ondansetron Market Facts & Figures by Country
5.8.1 Middle East and Africa Ondansetron Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa Ondansetron Sales by Country (2021-2032)
5.8.3 Middle East and Africa Ondansetron Revenue by Country (2021-2032)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries

6 Segment by Type
6.1 Global Ondansetron Sales by Type (2021-2032)
6.1.1 Global Ondansetron Sales by Type (2021-2032) & (kg)
6.1.2 Global Ondansetron Sales Market Share by Type (2021-2032)
6.2 Global Ondansetron Revenue by Type (2021-2032)
6.2.1 Global Ondansetron Sales by Type (2021-2032) & (US$ Million)
6.2.2 Global Ondansetron Revenue Market Share by Type (2021-2032)
6.3 Global Ondansetron Price by Type (2021-2032)

7 Segment by Application
7.1 Global Ondansetron Sales by Application (2021-2032)
7.1.1 Global Ondansetron Sales by Application (2021-2032) & (kg)
7.1.2 Global Ondansetron Sales Market Share by Application (2021-2032)
7.2 Global Ondansetron Revenue by Application (2021-2032)
7.2.1 Global Ondansetron Sales by Application (2021-2032) & (US$ Million)
7.2.2 Global Ondansetron Revenue Market Share by Application (2021-2032)
7.3 Global Ondansetron Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market
8.1 Ondansetron Value Chain Analysis
8.1.1 Ondansetron Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Ondansetron Production Mode & Process
8.2 Ondansetron Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Ondansetron Distributors
8.2.3 Ondansetron Customers

9 Global Ondansetron Analyzing Market Dynamics
9.1 Ondansetron Industry Trends
9.2 Ondansetron Industry Drivers
9.3 Ondansetron Industry Opportunities and Challenges
9.4 Ondansetron Industry Restraints

10 Report Conclusion
11 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Ondansetron Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Ondansetron Sales (kg) of Manufacturers (2021-2026)
Table 7. Global Ondansetron Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Ondansetron Revenue of Manufacturers (2021-2026)
Table 9. Global Ondansetron Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Ondansetron Average Price (USD/g) of Manufacturers (2021-2026)
Table 11. Global Ondansetron Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Ondansetron, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Ondansetron, Product Type & Application
Table 14. Global Ondansetron Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Ondansetron by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Sun Pharmaceuticals Company Information
Table 19. Sun Pharmaceuticals Business Overview
Table 20. Sun Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 21. Sun Pharmaceuticals Ondansetron Product Portfolio
Table 22. Sun Pharmaceuticals Recent Developments
Table 23. Sandoz Company Information
Table 24. Sandoz Business Overview
Table 25. Sandoz Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 26. Sandoz Ondansetron Product Portfolio
Table 27. Sandoz Recent Developments
Table 28. Qilu Pharmaceutical Company Information
Table 29. Qilu Pharmaceutical Business Overview
Table 30. Qilu Pharmaceutical Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 31. Qilu Pharmaceutical Ondansetron Product Portfolio
Table 32. Qilu Pharmaceutical Recent Developments
Table 33. Fuan Pharmaceutical Company Information
Table 34. Fuan Pharmaceutical Business Overview
Table 35. Fuan Pharmaceutical Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 36. Fuan Pharmaceutical Ondansetron Product Portfolio
Table 37. Fuan Pharmaceutical Recent Developments
Table 38. PKU HealthCare Company Information
Table 39. PKU HealthCare Business Overview
Table 40. PKU HealthCare Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 41. PKU HealthCare Ondansetron Product Portfolio
Table 42. PKU HealthCare Recent Developments
Table 43. Wockhardt Company Information
Table 44. Wockhardt Business Overview
Table 45. Wockhardt Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 46. Wockhardt Ondansetron Product Portfolio
Table 47. Wockhardt Recent Developments
Table 48. Aelida Healthcare Company Information
Table 49. Aelida Healthcare Business Overview
Table 50. Aelida Healthcare Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 51. Aelida Healthcare Ondansetron Product Portfolio
Table 52. Aelida Healthcare Recent Developments
Table 53. Beijing Sciecure Pharmaceutical Company Information
Table 54. Beijing Sciecure Pharmaceutical Business Overview
Table 55. Beijing Sciecure Pharmaceutical Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 56. Beijing Sciecure Pharmaceutical Ondansetron Product Portfolio
Table 57. Beijing Sciecure Pharmaceutical Recent Developments
Table 58. Jiangsu Hengrui Pharmaceuticals Company Information
Table 59. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 60. Jiangsu Hengrui Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 61. Jiangsu Hengrui Pharmaceuticals Ondansetron Product Portfolio
Table 62. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 63. Fosun Pharma Company Information
Table 64. Fosun Pharma Business Overview
Table 65. Fosun Pharma Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 66. Fosun Pharma Ondansetron Product Portfolio
Table 67. Fosun Pharma Recent Developments
Table 68. Harbin Medisan Company Information
Table 69. Harbin Medisan Business Overview
Table 70. Harbin Medisan Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 71. Harbin Medisan Ondansetron Product Portfolio
Table 72. Harbin Medisan Recent Developments
Table 73. CTX Lifesciences Company Information
Table 74. CTX Lifesciences Business Overview
Table 75. CTX Lifesciences Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 76. CTX Lifesciences Ondansetron Product Portfolio
Table 77. CTX Lifesciences Recent Developments
Table 78. Pfizer Company Information
Table 79. Pfizer Business Overview
Table 80. Pfizer Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 81. Pfizer Ondansetron Product Portfolio
Table 82. Pfizer Recent Developments
Table 83. Viatris Company Information
Table 84. Viatris Business Overview
Table 85. Viatris Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 86. Viatris Ondansetron Product Portfolio
Table 87. Viatris Recent Developments
Table 88. Dr. Reddy's Laboratories Company Information
Table 89. Dr. Reddy's Laboratories Business Overview
Table 90. Dr. Reddy's Laboratories Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 91. Dr. Reddy's Laboratories Ondansetron Product Portfolio
Table 92. Dr. Reddy's Laboratories Recent Developments
Table 93. Aurobindo Pharma Company Information
Table 94. Aurobindo Pharma Business Overview
Table 95. Aurobindo Pharma Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 96. Aurobindo Pharma Ondansetron Product Portfolio
Table 97. Aurobindo Pharma Recent Developments
Table 98. Zydus Lifesciences Company Information
Table 99. Zydus Lifesciences Business Overview
Table 100. Zydus Lifesciences Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 101. Zydus Lifesciences Ondansetron Product Portfolio
Table 102. Zydus Lifesciences Recent Developments
Table 103. Lupin Company Information
Table 104. Lupin Business Overview
Table 105. Lupin Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 106. Lupin Ondansetron Product Portfolio
Table 107. Lupin Recent Developments
Table 108. Hikma Pharmaceuticals Company Information
Table 109. Hikma Pharmaceuticals Business Overview
Table 110. Hikma Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 111. Hikma Pharmaceuticals Ondansetron Product Portfolio
Table 112. Hikma Pharmaceuticals Recent Developments
Table 113. Fresenius Kabi Company Information
Table 114. Fresenius Kabi Business Overview
Table 115. Fresenius Kabi Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 116. Fresenius Kabi Ondansetron Product Portfolio
Table 117. Fresenius Kabi Recent Developments
Table 118. Baxter Pharmaceuticals Company Information
Table 119. Baxter Pharmaceuticals Business Overview
Table 120. Baxter Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026)
Table 121. Baxter Pharmaceuticals Ondansetron Product Portfolio
Table 122. Baxter Pharmaceuticals Recent Developments
Table 123. Global Ondansetron Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 124. Global Ondansetron Sales by Region (2021-2026) & (kg)
Table 125. Global Ondansetron Sales Market Share by Region (2021-2026)
Table 126. Global Ondansetron Sales by Region (2027-2032) & (kg)
Table 127. Global Ondansetron Sales Market Share by Region (2027-2032)
Table 128. Global Ondansetron Revenue by Region (2021-2026) & (US$ Million)
Table 129. Global Ondansetron Revenue Market Share by Region (2021-2026)
Table 130. Global Ondansetron Revenue by Region (2027-2032) & (US$ Million)
Table 131. Global Ondansetron Revenue Market Share by Region (2027-2032)
Table 132. North America Ondansetron Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 133. North America Ondansetron Sales by Country (2021-2026) & (kg)
Table 134. North America Ondansetron Sales by Country (2027-2032) & (kg)
Table 135. North America Ondansetron Revenue by Country (2021-2026) & (US$ Million)
Table 136. North America Ondansetron Revenue by Country (2027-2032) & (US$ Million)
Table 137. Europe Ondansetron Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 138. Europe Ondansetron Sales by Country (2021-2026) & (kg)
Table 139. Europe Ondansetron Sales by Country (2027-2032) & (kg)
Table 140. Europe Ondansetron Revenue by Country (2021-2026) & (US$ Million)
Table 141. Europe Ondansetron Revenue by Country (2027-2032) & (US$ Million)
Table 142. Asia Pacific Ondansetron Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 143. Asia Pacific Ondansetron Sales by Country (2021-2026) & (kg)
Table 144. Asia Pacific Ondansetron Sales by Country (2027-2032) & (kg)
Table 145. Asia Pacific Ondansetron Revenue by Country (2021-2026) & (US$ Million)
Table 146. Asia Pacific Ondansetron Revenue by Country (2027-2032) & (US$ Million)
Table 147. South America Ondansetron Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 148. South America Ondansetron Sales by Country (2021-2026) & (kg)
Table 149. South America Ondansetron Sales by Country (2027-2032) & (kg)
Table 150. South America Ondansetron Revenue by Country (2021-2026) & (US$ Million)
Table 151. South America Ondansetron Revenue by Country (2027-2032) & (US$ Million)
Table 152. Middle East and Africa Ondansetron Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 153. Middle East and Africa Ondansetron Sales by Country (2021-2026) & (kg)
Table 154. Middle East and Africa Ondansetron Sales by Country (2027-2032) & (kg)
Table 155. Middle East and Africa Ondansetron Revenue by Country (2021-2026) & (US$ Million)
Table 156. Middle East and Africa Ondansetron Revenue by Country (2027-2032) & (US$ Million)
Table 157. Global Ondansetron Sales by Type (2021-2026) & (kg)
Table 158. Global Ondansetron Sales by Type (2027-2032) & (kg)
Table 159. Global Ondansetron Sales Market Share by Type (2021-2026)
Table 160. Global Ondansetron Sales Market Share by Type (2027-2032)
Table 161. Global Ondansetron Revenue by Type (2021-2026) & (US$ Million)
Table 162. Global Ondansetron Revenue by Type (2027-2032) & (US$ Million)
Table 163. Global Ondansetron Revenue Market Share by Type (2021-2026)
Table 164. Global Ondansetron Revenue Market Share by Type (2027-2032)
Table 165. Global Ondansetron Price by Type (2021-2026) & (USD/g)
Table 166. Global Ondansetron Price by Type (2027-2032) & (USD/g)
Table 167. Global Ondansetron Sales by Application (2021-2026) & (kg)
Table 168. Global Ondansetron Sales by Application (2027-2032) & (kg)
Table 169. Global Ondansetron Sales Market Share by Application (2021-2026)
Table 170. Global Ondansetron Sales Market Share by Application (2027-2032)
Table 171. Global Ondansetron Revenue by Application (2021-2026) & (US$ Million)
Table 172. Global Ondansetron Revenue by Application (2027-2032) & (US$ Million)
Table 173. Global Ondansetron Revenue Market Share by Application (2021-2026)
Table 174. Global Ondansetron Revenue Market Share by Application (2027-2032)
Table 175. Global Ondansetron Price by Application (2021-2026) & (USD/g)
Table 176. Global Ondansetron Price by Application (2027-2032) & (USD/g)
Table 177. Key Raw Materials
Table 178. Raw Materials Key Suppliers
Table 179. Ondansetron Distributors List
Table 180. Ondansetron Customers List
Table 181. Ondansetron Industry Trends
Table 182. Ondansetron Industry Drivers
Table 183. Ondansetron Industry Restraints
Table 184. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Ondansetron Product Image
Figure 5. Global Ondansetron Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Ondansetron Market Size (2021-2032) & (US$ Million)
Figure 7. Global Ondansetron Sales (2021-2032) & (kg)
Figure 8. Global Ondansetron Average Price (USD/g) & (2021-2032)
Figure 9. Tablets (including ODT) Product Image
Figure 10. Injection Product Image
Figure 11. ODF/OSF Product Image
Figure 12. Other Product Image
Figure 13. Hospital pharmacies Product Image
Figure 14. Retail pharmacies Product Image
Figure 15. Online pharmacies Product Image
Figure 16. Global Ondansetron Revenue Share by Manufacturers in 2025
Figure 17. Global Manufacturers of Ondansetron, Manufacturing Sites & Headquarters
Figure 18. Global Top 5 and 10 Ondansetron Players Market Share by Revenue in 2025
Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 20. Global Ondansetron Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 21. Global Ondansetron Sales by Region in 2025
Figure 22. Global Ondansetron Revenue by Region in 2025
Figure 23. North America Ondansetron Market Size by Country in 2025
Figure 24. North America Ondansetron Sales Market Share by Country (2021-2032)
Figure 25. North America Ondansetron Revenue Market Share by Country (2021-2032)
Figure 26. United States Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 27. Canada Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 28. Mexico Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Europe Ondansetron Market Size by Country in 2025
Figure 30. Europe Ondansetron Sales Market Share by Country (2021-2032)
Figure 31. Europe Ondansetron Revenue Market Share by Country (2021-2032)
Figure 32. Germany Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. France Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. U.K. Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. Italy Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Russia Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Spain Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Netherlands Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Switzerland Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Sweden Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Poland Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. Asia Pacific Ondansetron Market Size by Country in 2025
Figure 43. Asia Pacific Ondansetron Sales Market Share by Country (2021-2032)
Figure 44. Asia Pacific Ondansetron Revenue Market Share by Country (2021-2032)
Figure 45. China Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. Japan Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. South Korea Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. India Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Australia Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Taiwan Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Southeast Asia Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Southeast Asia Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. South America Ondansetron Market Size by Country in 2025
Figure 54. South America Ondansetron Sales Market Share by Country (2021-2032)
Figure 55. South America Ondansetron Revenue Market Share by Country (2021-2032)
Figure 56. Brazil Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. Argentina Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Chile Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. Colombia Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. Middle East and Africa Ondansetron Market Size by Country in 2025
Figure 61. Middle East and Africa Ondansetron Sales Market Share by Country (2021-2032)
Figure 62. Middle East and Africa Ondansetron Revenue Market Share by Country (2021-2032)
Figure 63. Egypt Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 64. South Africa Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 65. Israel Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 66. Türkiye Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 67. GCC Countries Ondansetron Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 68. Global Ondansetron Sales Market Share by Type (2021-2032)
Figure 69. Global Ondansetron Revenue Market Share by Type (2021-2032)
Figure 70. Global Ondansetron Price (USD/g) by Type (2021-2032)
Figure 71. Global Ondansetron Sales Market Share by Application (2021-2032)
Figure 72. Global Ondansetron Revenue Market Share by Application (2021-2032)
Figure 73. Global Ondansetron Price (USD/g) by Application (2021-2032)
Figure 74. Ondansetron Value Chain
Figure 75. Ondansetron Production Mode & Process
Figure 76. Direct Comparison with Distribution Share
Figure 77. Distributors Profiles
Figure 78. Ondansetron Industry Opportunities and Challenges